Precision BioSciences Joins Russell 2000 Index
Event summary
- Precision BioSciences added to the Russell 2000 Index effective June 26, 2026.
- Inclusion follows annual reconstitution based on market capitalization.
- Company advancing two clinical programs with cash runway through 2028.
The big picture
Precision BioSciences' addition to the Russell 2000 Index expands its visibility among institutional investors, coming at a critical juncture as it advances two clinical-stage gene editing therapies. The inclusion reflects growing market recognition of the company's ARCUS platform technology in addressing high-unmet medical needs. With $57 billion in assets under management tracking the Russell 2000, this move could significantly impact Precision BioSciences' access to capital and investor engagement.
What we're watching
- Institutional Interest
- How Russell 2000 inclusion will affect engagement with large investors.
- Clinical Progress
- Whether the company can maintain momentum in its HBV and DMD programs.
- Financial Runway
- The pace at which Precision BioSciences burns through its cash reserves.
Related topics